EA201890684A1 - Производные фториндола в качестве положительных аллостерических модуляторов мускаринового рецептора m1 - Google Patents
Производные фториндола в качестве положительных аллостерических модуляторов мускаринового рецептора m1Info
- Publication number
- EA201890684A1 EA201890684A1 EA201890684A EA201890684A EA201890684A1 EA 201890684 A1 EA201890684 A1 EA 201890684A1 EA 201890684 A EA201890684 A EA 201890684A EA 201890684 A EA201890684 A EA 201890684A EA 201890684 A1 EA201890684 A1 EA 201890684A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- receptor
- positive allosteric
- allosteric modulators
- fluorindol
- muscarine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Abstract
Настоящее изобретение относится к соединению формулы (I) или его стереоизомерам и фармацевтически приемлемым солям в качестве положительных аллостерических модуляторов мускаринового рецептора M1. Это изобретение также относится к способам получения таких соединений и к фармацевтическим композициям, включающим такие соединения. Соединения согласно этому изобретению могут быть использованы в лечении различных нарушений, связанных с мускариновым рецептором M1.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN4809CH2015 | 2015-09-10 | ||
PCT/IB2016/054290 WO2017042643A1 (en) | 2015-09-10 | 2016-07-19 | Fluoroindole derivatives as muscarinic m1 receptor positive allosteric modulators |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201890684A1 true EA201890684A1 (ru) | 2018-10-31 |
EA033826B1 EA033826B1 (ru) | 2019-11-29 |
Family
ID=56618200
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201890684A EA033826B1 (ru) | 2015-09-10 | 2016-07-19 | Производные фториндола в качестве положительных аллостерических модуляторов мускаринового рецептора m1 |
Country Status (28)
Country | Link |
---|---|
US (1) | US10294217B2 (ru) |
EP (1) | EP3347349B1 (ru) |
JP (1) | JP6553811B2 (ru) |
KR (1) | KR102068237B1 (ru) |
CN (1) | CN108026073B (ru) |
AU (1) | AU2016320645B2 (ru) |
BR (1) | BR112018004719B1 (ru) |
CA (1) | CA2997956C (ru) |
CY (1) | CY1122321T1 (ru) |
DK (1) | DK3347349T3 (ru) |
EA (1) | EA033826B1 (ru) |
ES (1) | ES2750868T3 (ru) |
HK (1) | HK1247914A1 (ru) |
HR (1) | HRP20191869T1 (ru) |
HU (1) | HUE047056T2 (ru) |
IL (1) | IL257869A (ru) |
LT (1) | LT3347349T (ru) |
MA (1) | MA42769B1 (ru) |
MD (1) | MD3347349T2 (ru) |
ME (1) | ME03571B (ru) |
MX (1) | MX2018002821A (ru) |
NZ (1) | NZ740587A (ru) |
PL (1) | PL3347349T3 (ru) |
PT (1) | PT3347349T (ru) |
RS (1) | RS59473B1 (ru) |
SI (1) | SI3347349T1 (ru) |
WO (1) | WO2017042643A1 (ru) |
ZA (1) | ZA201801463B (ru) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111212840B (zh) | 2017-10-18 | 2022-07-22 | 苏文生命科学有限公司 | 作为毒蕈碱m1受体正向别构调节剂的杂芳基化合物 |
US11278530B2 (en) * | 2017-10-27 | 2022-03-22 | Suven Life Sciences Limited | Polycyclic amides as muscarinic M1 receptor positive allosteric modulators |
JP2023512821A (ja) | 2020-02-04 | 2023-03-29 | マインドセット ファーマ インコーポレイテッド | 中枢神経系障害の治療のためのセロトニン作動性幻覚薬としての3-ピロリジンインドール誘導体 |
WO2023114224A1 (en) | 2021-12-13 | 2023-06-22 | Sage Therapeutics, Inc. | Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators |
CN115385849B (zh) * | 2022-09-14 | 2024-01-26 | 南通瑞合达医药科技有限公司 | 一种N-Boc-3-氟-4-哌啶酮提纯的方法 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60123485A (ja) | 1983-12-08 | 1985-07-02 | Yoshitomi Pharmaceut Ind Ltd | インド−ル−3−カルボキサミド誘導体 |
JP2004502642A (ja) | 2000-02-11 | 2004-01-29 | ブリストル−マイヤーズ スクイブ カンパニー | カンナビノイドレセプターモジュレーター、それらの製造方法、および呼吸系および非呼吸系疾患の処置のためのカンナビノイドレセプターモジュレーターの使用 |
CA2631917A1 (en) | 2005-12-05 | 2007-06-14 | Merck & Co., Inc. | Quinolone m1 receptor positive allosteric modulators |
BR112012003464B8 (pt) * | 2009-08-31 | 2021-05-25 | Merck Sharp & Dohme | compostos de piranil aril metil benzoquinaozlinona, uso dos mesmos, e, composição farmacêutica |
US9199939B2 (en) * | 2009-12-17 | 2015-12-01 | Merck Sharp & Dohme Corp. | Quinoline amide M1 receptor positive allosteric modulators |
US8883850B2 (en) * | 2010-05-28 | 2014-11-11 | Merck Sharp & Dohme Corp. | Naphthalene carboxamide M1 receptor positive allosteric modulators |
TW201512197A (zh) | 2013-08-30 | 2015-04-01 | Hoffmann La Roche | 吡咯并吡啶或吡唑并吡啶衍生物 |
CA2918925A1 (en) * | 2013-09-27 | 2015-04-02 | F. Hoffmann-La Roche Ag | Indol and indazol derivatives |
GB201317363D0 (en) | 2013-10-01 | 2013-11-13 | Eisai Ltd | Novel compounds |
US9708278B2 (en) | 2013-11-27 | 2017-07-18 | Vanderbilt University | Substituted 4-benzyl-3,4-dihydro-2H-benzo[B][1,4]oxazine-2-carboxamide analogs as positive allosteric modulators of muscarinic acetycholine receptor M1 |
-
2016
- 2016-07-19 ES ES16750259T patent/ES2750868T3/es active Active
- 2016-07-19 KR KR1020187009938A patent/KR102068237B1/ko active IP Right Grant
- 2016-07-19 EA EA201890684A patent/EA033826B1/ru unknown
- 2016-07-19 SI SI201630447T patent/SI3347349T1/sl unknown
- 2016-07-19 US US15/758,313 patent/US10294217B2/en active Active
- 2016-07-19 ME MEP-2019-288A patent/ME03571B/me unknown
- 2016-07-19 DK DK16750259T patent/DK3347349T3/da active
- 2016-07-19 CA CA2997956A patent/CA2997956C/en active Active
- 2016-07-19 MX MX2018002821A patent/MX2018002821A/es unknown
- 2016-07-19 WO PCT/IB2016/054290 patent/WO2017042643A1/en active Application Filing
- 2016-07-19 MD MDE20180689 patent/MD3347349T2/ro unknown
- 2016-07-19 NZ NZ740587A patent/NZ740587A/en unknown
- 2016-07-19 RS RS20191328A patent/RS59473B1/sr unknown
- 2016-07-19 JP JP2018512868A patent/JP6553811B2/ja active Active
- 2016-07-19 BR BR112018004719-8A patent/BR112018004719B1/pt active IP Right Grant
- 2016-07-19 LT LT16750259T patent/LT3347349T/lt unknown
- 2016-07-19 EP EP16750259.0A patent/EP3347349B1/en active Active
- 2016-07-19 MA MA42769A patent/MA42769B1/fr unknown
- 2016-07-19 PL PL16750259T patent/PL3347349T3/pl unknown
- 2016-07-19 PT PT167502590T patent/PT3347349T/pt unknown
- 2016-07-19 CN CN201680052764.2A patent/CN108026073B/zh active Active
- 2016-07-19 HU HUE16750259A patent/HUE047056T2/hu unknown
- 2016-07-19 AU AU2016320645A patent/AU2016320645B2/en active Active
-
2018
- 2018-03-02 ZA ZA2018/01463A patent/ZA201801463B/en unknown
- 2018-03-05 IL IL257869A patent/IL257869A/en active IP Right Grant
- 2018-06-04 HK HK18107271.5A patent/HK1247914A1/zh unknown
-
2019
- 2019-10-15 HR HRP20191869TT patent/HRP20191869T1/hr unknown
- 2019-10-16 CY CY20191101086T patent/CY1122321T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SA518392101B1 (ar) | ROR-Gamma مشتقات البنزيميدازول في صورة مُعدلات لـ | |
MX2022012317A (es) | Oxisteroles y metodos de uso de los mismos. | |
PH12018500065A1 (en) | Oxysterols and methods of use thereof | |
PH12018500061A1 (en) | Oxysterols and methods of use thereof | |
GEP20207105B (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors | |
EA201791256A1 (ru) | Производные хиназолина, применяемые для лечения вич | |
EA201690223A1 (ru) | Ингибиторы фактора в комплемента на основе производных пиперидинилиндола и их применение | |
MX2019002180A (es) | Moduladores alostericos positivos del receptor m1 muscarinico. | |
EA201891063A1 (ru) | Производные дигидроимидазопиразинона, применимые в лечении рака | |
EA201792594A1 (ru) | Положительные аллостерические модуляторы мусаринового рецептора м1 | |
EA201891179A1 (ru) | N-замещенные индольные производные в качестве модуляторов pge2 рецепторов | |
EA201692037A1 (ru) | Пирролидиновые модуляторы gpr40 для лечения расстройств, таких как диабет | |
EA201890684A1 (ru) | Производные фториндола в качестве положительных аллостерических модуляторов мускаринового рецептора m1 | |
EA201791600A1 (ru) | Производные гидроксиалкилпиперазина в качестве модуляторов cxcr3 рецептора | |
EA201791829A1 (ru) | Амидные соединения в качестве агонистов рецептора 5-ht | |
EA201790830A1 (ru) | Ингибиторы альдостеронсинтазы | |
EA201790253A1 (ru) | Ингибиторы альдостеронсинтазы | |
MX2017013099A (es) | Metodos para el tratamiento de trastornos inflamatorios. | |
EA201700356A1 (ru) | Новые циклопропанбензофуранилпиридопиразиндионы | |
EA201791480A1 (ru) | Новые производные бензимидазола в качестве антигистаминных агентов | |
EA202090925A1 (ru) | Гетероарильные соединения в качестве позитивных аллостерических модуляторов мускаринового рецептора m1 | |
EA201691252A1 (ru) | Соединения индазола в качестве агонистов 5-ht-рецептора | |
PH12016500980B1 (en) | Amide derivatives for gpr119 agonist | |
MX2017013103A (es) | Metodos para el tratamiento de trastornos cardiovasculares. | |
EA201791398A1 (ru) | Производные фумагиллола |